TELA Company Profile and Key Details

TELA has shown weak momentum, losing -12.01% over the past week and -39.04% over the past quarter, though year-to-date performance is down -20.96%. Short-term trend indicators are bullishly aligned (SMA20 -1.18%, SMA50 -16.23%, SMA200 -41.97%). The stock’s 14-day RSI is 44.06 (neutral), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -69.59% below its high and over 22.61% above its low. Average 10-day trading volume of 60.76 thousand shares is below the 3-month average of 164.77 thousand, indicating normal recent market interest.

TELA Bio, Inc. has 39.62 million shares outstanding. The public float is 18.42 million shares, elevated short interest at 1.47% of float. This equals 460.50 thousand shares. The short ratio is 5.85 days. Institutional investors hold 77.65% of the float. Insiders own 8.45%. EW HEALTHCARE PARTNERS FUND 2, L.P. holds 7.71 million shares, EW Healthcare Partners Fund 2-UGP, LLC has 4.11 million shares and ORBIMED ADVISORS LLC has 2.41 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

TELA Bio, Inc. generated EPS of -$0.89 over the past year. Five-year average earnings growth is 12.91%. Wall Street analysts project EPS growth of 35.31% annually over the next five years. The latest quarter delivered EPS of -$0.19. The next quarter is forecast at -$0.18. Next year's EPS is expected at $20.75. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 3 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $1.25. The high target offers 845.95% upside. The low target suggests 68.92% downside. The mean target is $4.61. This offers 522.97% upside. TELA Bio, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 13, 2025, missed forecasts by 11.41%. The prior quarter beat by 22.22%. Over the last six quarters, Apple has recorded several small beats. These include 13.33% in August 12, 2024.

TELA Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.16. This means the shares are trading below this model’s fair value.

TELA Bio, Inc. (NASDAQ:TELA) shares are down -20.96% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows TELA Bio, Inc. trading at a premium to the broader market with a P/E of -0.88. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $10.01, suggesting 1260.42% upside. Our AI forecast model points to short-term strength (3.29% over two weeks), a medium-term fall (-32.05% over three months), and a longer-term loss (-41.56% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that TELA Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.29%, with price expected at $0.76 by March 30, 2026, within a range of $0.71 to $0.81 3-Month Outlook: Projected fall of -32.05%, reaching $0.50 by June 12, 2026, with a range of $0.43 to $0.56. 1-Year Outlook: Projected loss of -41.56%, with price at $0.43 by March 16, 2027, within a range of $0.00 to $0.00.

TELA Bio, Inc. (NASDAQ:TELA) closed at $0.85 USD, gaining $0.11 (15.52%) from the previous close of $0.74. The stock is currently mid-range between its 52-week high and low $0.67 and $2.48. With a market capitalization of about $37.85 million, TELA Bio, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.89). Key stats such as the average daily volume over the past year has been around 162.57 thousand shares, volume is running light vs its 52-week average. Headquartered in Malvern, PA, TELA Bio, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Antony Koblish, the company employs approximately 209 people and listed since November 08, 2019. TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy.

TELA Bio, Inc. trades at a P/E ratio of -0.88, slightly below the S&P 500 average, with a price-to-sales ratio of 0.44 and a price-to-book ratio of 21.96 reflecting a rich premium to book value. The P/FCF stands at -1.06, also above market averages. Compared to sector medians, TELA Bio, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.